Naoki Kumashiro

3.0k total citations · 1 hit paper
43 papers, 2.2k citations indexed

About

Naoki Kumashiro is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Epidemiology. According to data from OpenAlex, Naoki Kumashiro has authored 43 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Endocrinology, Diabetes and Metabolism, 14 papers in Molecular Biology and 12 papers in Epidemiology. Recurrent topics in Naoki Kumashiro's work include Diabetes Treatment and Management (14 papers), Liver Disease Diagnosis and Treatment (10 papers) and Metabolism, Diabetes, and Cancer (10 papers). Naoki Kumashiro is often cited by papers focused on Diabetes Treatment and Management (14 papers), Liver Disease Diagnosis and Treatment (10 papers) and Metabolism, Diabetes, and Cancer (10 papers). Naoki Kumashiro collaborates with scholars based in Japan and United States. Naoki Kumashiro's co-authors include Takahisa Hirose, Gerald I. Shulman, Fumika Shigiyama, Varman T. Samuel, Dongyan Zhang, Hiroshi Uchino, Mario Kahn, Derek M. Erion, Gary W. Cline and Hirotaka Watada and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Hepatology.

In The Last Decade

Naoki Kumashiro

42 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease

2011 450 citations Naoki Kumashiro, Derek M. Erion et al. profile →

Peers

Countries citing papers authored by Naoki Kumashiro

Since Specialization

Citations

This map shows the geographic impact of Naoki Kumashiro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Kumashiro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Kumashiro more than expected).

Fields of papers citing papers by Naoki Kumashiro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Kumashiro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Kumashiro. The network helps show where Naoki Kumashiro may publish in the future.

Co-authorship network of co-authors of Naoki Kumashiro

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Kumashiro. A scholar is included among the top collaborators of Naoki Kumashiro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Kumashiro. Naoki Kumashiro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of the effects of pemafibrate and omega-3 fatty acid ethyl on fatty liver index in patients with dyslipidemia treated with statin: a sub-analysis from the PROUD48 study 2025 ·Frontiers in Endocrinology ·Yasutaka Takeda, Masato Furuhashi, Ichiro Sakuma, Shinya Hiramitsu, (unknown), Shinichiro Ueda, Naoki Kumashiro, Masaru Sakurai	2
2	Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue‐specific insulin sensitivity in patients with early‐stage type 2 diabetes with non‐alcoholic fatty liver disease: A prospective randomized study 2023 ·Diabetes Obesity and Metabolism ·(unknown), Fumika Shigiyama, Naoki Kumashiro	33
3	Comparison of the effects of sitagliptin and dapagliflozin on time in range in Japanese patients with type 2 diabetes stratified by body mass index: A sub‐analysis of the DIVERSITY‐CVR study 2023 ·Diabetes Obesity and Metabolism ·(unknown), (unknown), Fumika Shigiyama, Naoki Kumashiro, Takahisa Hirose	7
4	Changes in subjective sleep quality in patients with type 2 diabetes who did not use Sleep agents: a cross-sectional study according to age and clinical background 2021 ·Diabetology International ·(unknown), Naoki Kumashiro, Fumika Shigiyama, Masahiko Miyagi, Yukio Ando, Hiroshi Uchino, Takahisa Hirose	2
5	Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia 2020 ·Diabetes Research and Clinical Practice ·(unknown), Fumika Shigiyama, Yukio Ando, Masahiko Miyagi, Hiroshi Uchino, Takahisa Hirose, Naoki Kumashiro	15
6	Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR) 2020 ·Cardiovascular Diabetology ·(unknown), Fumika Shigiyama, (unknown), Yosuke Okada, Takamasa Ichijo, (unknown), Toru Hiyoshi, Ikuo Inoue, (unknown), Hidenori Yoshii, Takahisa Hirose, Naoki Kumashiro	75
7	Rationale, Design for the ASSET Study: A Prospective Randomized Study Comparing Empagliflozin’s Effect to Sitagliptin on Cardiac Fat Accumulation/Function in Patients with Type 2 Diabetes 2019 ·Diabetes Therapy ·Fumika Shigiyama, (unknown), Shinji Hisatake, Nobuyuki Shiraga, Takanori Ikeda, Takahisa Hirose, Naoki Kumashiro	3
8	Whole hepatic lipid volume quantification and color mapping by multi‐slice and multi‐point magnetic resonance imaging 2019 ·Hepatology Research ·(unknown), Fumika Shigiyama, Noritaka Wakui, Hidenari Nagai, Kazutoshi Shibuya, Nobuyuki Shiraga, Takahisa Hirose, Naoki Kumashiro	4
9	Up-Titration Strategy After DPP-4 Inhibitor-Based Oral Therapy for Type 2 Diabetes: A Randomized Controlled Trial Shifting to a Single-Dose GLP-1 Enhancer Versus Adding a Variable Basal Insulin Algorithm 2018 ·Diabetes Therapy ·Masahiko Miyagi, Hiroshi Uchino, Naoki Kumashiro, (unknown), Koki Shin, (unknown), (unknown), Motoyuki Tamaki, Munehide Matsuhisa, Takahisa Hirose	1
10	Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A randomized, open‐label, prospective study 2018 ·Journal of Diabetes Investigation ·(unknown), Hiroshi Uchino, Fumika Shigiyama, (unknown), (unknown), (unknown), (unknown), Masahiko Miyagi, Hiroshi Yoshino, Yukio Ando, Naoki Kumashiro, Takahisa Hirose	5
11	A case of bullous pemphigoid associated with the administration of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor 2018 ·(unknown), Hiroshi Uchino, (unknown), (unknown), Hiroshi Yoshino, Masahiko Miyagi, Naoki Kumashiro, Takahisa Hirose	5
12	Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study 2018 ·Cardiovascular Diabetology ·Fumika Shigiyama, Naoki Kumashiro, (unknown), Takahisa Hirose	3
13	Glycemic Variability in Type 1 Diabetes Compared with Degludec and Glargine on the Morning Injection: An Open-label Randomized Controlled Trial 2017 ·Diabetes Therapy ·(unknown), Hiroshi Uchino, (unknown), (unknown), Masahiko Miyagi, Naoki Kumashiro, Hiroshi Yoshino, Yukio Ando, Takahisa Hirose	26
14	Acute suppurative thyroiditis in infected thyroid cyst in an adult patient under hemodialysis 2017 ·Clinical Case Reports ·(unknown), Hiroshi Yoshino, (unknown), Naoki Kumashiro, Yukio Ando, Hiroshi Uchino, Kumiko Tsuboi, Takahisa Hirose	4
15	Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study 2017 ·Cardiovascular Diabetology ·Fumika Shigiyama, Naoki Kumashiro, Masahiko Miyagi, (unknown), Eiichiro Kanda, Hiroshi Uchino, Takahisa Hirose	199
16	Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis 2014 ·Nature Medicine ·Rachel J. Perry, Xian‐Man Zhang, Dongyan Zhang, Naoki Kumashiro, João Paulo Camporez, Gary W. Cline, Douglas L. Rothman, Gerald I. Shulman	151
17	Acute focal bacterial nephritis in an occupational allergy 2014 ·The Lancet Infectious Diseases ·(unknown), Hiroshi Uchino, (unknown), (unknown), Masahiko Miyagi, Naoki Kumashiro, Takahisa Hirose	3
18	Role of patatin-like phospholipase domain-containing 3 on lipid-induced hepatic steatosis and insulin resistance in rats 2012 ·Hepatology ·Naoki Kumashiro, Toru Yoshimura, Jennifer Cantley, Sachin Majumdar, Fitsum Guebre‐Egziabher, Romy Kursawe, Daniel F. Vatner, (unknown), Mario Kahn, Derek M. Erion, Xian‐Man Zhang, Dongyan Zhang, Vara Prasad Manchem, Sanjay Bhanot, Glenn S. Gerhard, Kitt Falk Petersen, Gary W. Cline, Varman T. Samuel, Gerald I. Shulman	75
19	Determinants of intramyocellular lipid accumulation after dietary fat loading in non-obese men 2010 ·Journal of Diabetes Investigation ·Yuko Sakurai, Yoshifumi Tamura, Kageumi Takeno, Naoki Kumashiro, Fumihiko Sato, Saori Kakehi, Shin‐ichi Ikeda, Yuji Ogura, (unknown), Hisashi Naıto, Shizuo Katamoto, Yoshio Fujitani, Takahisa Hirose, Ryuzo Kawamori, Hirotaka Watada	24
20	Measuring Effectiveness of Glimepiride Titration Using SMBG in Patients with Mild Type 2 Diabetes 2009 ·Akio Kanazawa, Tomoaki Shimizu, Chie Ebato, Yuko Sakurai, Naoki Kumashiro, (unknown), Takahisa Hirose, Yasushi Tanaka, Ryuzo Kawamori, Hirotaka Watada	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact